Evidence map›Paper›PMID 42060068›Full record

ArticleCerebellum (London, England)2026

Behavioral and Personality Changes as the First Manifestation of Spinocerebellar Ataxia Type 2.

Davide Vilella, Daniele Urso, Agnese Valguarnera, Giuseppe Volpe, Maria Accadia, Chiara Zecca, Alessandra Vitulli, Roberto De Blasi, Alessandro Bertolino, Giancarlo Logroscino

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Davide VilellaCenter for Neurodegenerative Diseases and The Aging Brain, University of Bari Aldo Moro at Pia Fondazione ¨Card. G. Panico¨, San Pio X, Tricase, Lecce, 73039, Italy. d.vilella@piafondazionepanico.it.
Daniele UrsoCenter for Neurodegenerative Diseases and The Aging Brain, University of Bari Aldo Moro at Pia Fondazione ¨Card. G. Panico¨, San Pio X, Tricase, Lecce, 73039, Italy.
Agnese ValguarneraDepartment of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari Aldo Moro, Piazza Giulio Cesare, 11, Bari, 70124, Italy.
Giuseppe VolpeDepartment of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari Aldo Moro, Piazza Giulio Cesare, 11, Bari, 70124, Italy.
Maria AccadiaCenter for Neurodegenerative Diseases and The Aging Brain, University of Bari Aldo Moro at Pia Fondazione ¨Card. G. Panico¨, San Pio X, Tricase, Lecce, 73039, Italy.
Chiara ZeccaCenter for Neurodegenerative Diseases and The Aging Brain, University of Bari Aldo Moro at Pia Fondazione ¨Card. G. Panico¨, San Pio X, Tricase, Lecce, 73039, Italy.
Alessandra VitulliCenter for Neurodegenerative Diseases and The Aging Brain, University of Bari Aldo Moro at Pia Fondazione ¨Card. G. Panico¨, San Pio X, Tricase, Lecce, 73039, Italy.
Roberto De BlasiCenter for Neurodegenerative Diseases and The Aging Brain, University of Bari Aldo Moro at Pia Fondazione ¨Card. G. Panico¨, San Pio X, Tricase, Lecce, 73039, Italy.
Alessandro BertolinoDepartment of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari Aldo Moro, Piazza Giulio Cesare, 11, Bari, 70124, Italy.
Giancarlo LogroscinoCenter for Neurodegenerative Diseases and The Aging Brain, University of Bari Aldo Moro at Pia Fondazione ¨Card. G. Panico¨, San Pio X, Tricase, Lecce, 73039, Italy.

Funding

Tecnopolo per la Medicina di Precisione B84I18000540002
6 · The paper itself

Abstract

Background. Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant neurodegenerative disorder caused by CAG repeat expansion in the ATXN2 gene. Although classically characterized by progressive cerebellar ataxia and oculomotor abnormalities, increasing evidence indicates that SCA2 is a multisystem disorder with prominent cognitive, behavioral, and psychiatric manifestations. These non-motor symptoms may precede overt motor signs, leading to diagnostic challenges and misdiagnosis as primary psychiatric conditions. Case Presentation. We report the case of a 59-year-old man with a several-year history of progressive behavioral and emotional dysregulation, initially diagnosed as a personality disorder. Prominent features included irritability, impulsivity, disinhibition, hypersexuality, altered eating behavior, and recurrent self-endangering suicidal gestures, with relatively preserved functional autonomy. Neurological examination revealed subtle cerebellar signs. Neuropsychological assessment showed impaired verbal memory with preserved recognition and borderline attentional–executive deficits, consistent with cerebello–frontal dysfunction. Brain magnetic resonance imaging (MRI) demonstrated moderate-to-severe cerebellar and brainstem atrophy, while dopamine transporter SPECT revealed severe bilateral presynaptic dopaminergic denervation. Cerebrospinal fluid biomarkers excluded Alzheimer’s disease. Genetic testing confirmed SCA2 with 38 CAG repeats in ATXN2. Conclusions. This case illustrates an atypical presentation of SCA2 in which behavioral and psychiatric symptoms preceded motor manifestations by several years. Recognition of such presentations is crucial to avoid misdiagnosis, reduce diagnostic delay, and enable timely genetic counselling and multidisciplinary management, reinforcing the concept of SCA2 as a multisystem neurodegenerative disorder.

Indexed as

Personality DisordersSpinocerebellar AtaxiasAtaxin-2HumansMagnetic Resonance ImagingMaleMiddle AgedAtaxin-2ATXN2 protein, humanCerebellar cognitive affective syndromeprodromal symptomsPsychiatric symptomsSpinocerebellar ataxias

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.